Drug Profile
Research programme: cancer therapeutics - Array BioPharma/Loxo Oncology
Alternative Names: LOXO-102; LOXO-103; LOXO-104Latest Information Update: 20 Feb 2019
Price :
$50
*
At a glance
- Originator Array BioPharma
- Developer Array BioPharma; Loxo Oncology
- Class Antineoplastics; Small molecules
- Mechanism of Action Fibroblast growth factor receptor antagonists; Fms-like tyrosine kinase 3 inhibitors; Proto oncogene protein c ret inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Cancer
Highest Development Phases
- No development reported Cancer